newly
diagnosed
treatment
information
research &
trials
webcasts find
support
seminars
& meetings
events doctors nurses advocacy about
IMF
helping
the IMF
 
      new & noteworthy     
  Share via del.icio.us Share via Digg

:
Help fund research and important educational programs.
more..

WHAT IS MYELOMA? : more..


PATIENT SERVICES : Reimbursement, legal, and other services.
more..

MYELOMA MANAGER™ : Capture your lab results and see how they change over time. more..

NEXPROFILER™ :
Treatment information tailored to your diagnosis.
more..

FREE MYELOMA INFO PACK : Order one today. more..

Read the MYELOMA MINUTE :
Our free e-mail newsletter.
more..

Read MYELOMA TODAY :
And get a free subscription.
more..

IMF Privacy Policy : The IMF is committed to protecting the security of your personal and health information. more..

 
Dr. Rajkumar - ASH 2008 - An Overview of the 50th ASH Annual Meeting and Exposition
December 6-9, 2008
San Francisco, CA

12.15.08


The new proteasome inhibitor Carfilzomib seems to have activity even in patients who have failed
bortezomib and/or lenalidomide. And that is very promising.



To view the video full screen, click on the small button next to the volume control in the lower right hand corner.

We thank our web site sponsors

Amgen

Binding Site

Celgene Corporation

Proteolix

We welcome our international partners:
Canada Czech Republic Europe Israel Japan Latin America
Copyright 2009. International Myeloma Foundation. All Rights Reserved.

International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421
USA
phone: 800-452-2873 (US and Canada)
818-487-7455 (elsewhere)
fax: 818-487-7454
email: TheIMF@myeloma.org

This page last modified on ( 12.15.08 )
International Myeloma Foundation Articles Master List International Myeloma Foundation Events Master List International Myeloma Foundation Support Groups Master List International Myeloma Foundation PDF Master List